Results obtained with combination therapy of VM-26, Natulan and Prednisolone in generalized Hodgkin's disease

S. Eckhardt, E. Dobrentey, I. Bodrogi

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

By evaluating the results obtained in 50 patients the authors stated that VM 26 given in combination with Natulan and prednisolone is a drug of value in the therapy of generalized Hodgkin's disease. It causes milder side effects than drugs previously used in combination therapy. Complete or partial remissions were obtained in 84% of patients treated. 75% of the therapy resistant cases proved to be Hodgkin's sarcoma by the postmortem examination. Remission lasted longer in stage III than in stage IV and the previously untreated patients responded better than the treated ones. Definite correlation could not be revealed between histologic type and duration of remission.

Original languageEnglish
Pages (from-to)248-254
Number of pages7
JournalChemotherapy
Volume21
Issue number3-4
Publication statusPublished - 1975

Fingerprint

Teniposide
Procarbazine
Prednisolone
Hodgkin Disease
Drug-Related Side Effects and Adverse Reactions
Sarcoma
Autopsy
Therapeutics
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Pharmacology

Cite this

Results obtained with combination therapy of VM-26, Natulan and Prednisolone in generalized Hodgkin's disease. / Eckhardt, S.; Dobrentey, E.; Bodrogi, I.

In: Chemotherapy, Vol. 21, No. 3-4, 1975, p. 248-254.

Research output: Contribution to journalArticle

@article{04192fd8e7674311bf6acd63696613e4,
title = "Results obtained with combination therapy of VM-26, Natulan and Prednisolone in generalized Hodgkin's disease",
abstract = "By evaluating the results obtained in 50 patients the authors stated that VM 26 given in combination with Natulan and prednisolone is a drug of value in the therapy of generalized Hodgkin's disease. It causes milder side effects than drugs previously used in combination therapy. Complete or partial remissions were obtained in 84{\%} of patients treated. 75{\%} of the therapy resistant cases proved to be Hodgkin's sarcoma by the postmortem examination. Remission lasted longer in stage III than in stage IV and the previously untreated patients responded better than the treated ones. Definite correlation could not be revealed between histologic type and duration of remission.",
author = "S. Eckhardt and E. Dobrentey and I. Bodrogi",
year = "1975",
language = "English",
volume = "21",
pages = "248--254",
journal = "Chemotherapy",
issn = "0009-3157",
publisher = "S. Karger AG",
number = "3-4",

}

TY - JOUR

T1 - Results obtained with combination therapy of VM-26, Natulan and Prednisolone in generalized Hodgkin's disease

AU - Eckhardt, S.

AU - Dobrentey, E.

AU - Bodrogi, I.

PY - 1975

Y1 - 1975

N2 - By evaluating the results obtained in 50 patients the authors stated that VM 26 given in combination with Natulan and prednisolone is a drug of value in the therapy of generalized Hodgkin's disease. It causes milder side effects than drugs previously used in combination therapy. Complete or partial remissions were obtained in 84% of patients treated. 75% of the therapy resistant cases proved to be Hodgkin's sarcoma by the postmortem examination. Remission lasted longer in stage III than in stage IV and the previously untreated patients responded better than the treated ones. Definite correlation could not be revealed between histologic type and duration of remission.

AB - By evaluating the results obtained in 50 patients the authors stated that VM 26 given in combination with Natulan and prednisolone is a drug of value in the therapy of generalized Hodgkin's disease. It causes milder side effects than drugs previously used in combination therapy. Complete or partial remissions were obtained in 84% of patients treated. 75% of the therapy resistant cases proved to be Hodgkin's sarcoma by the postmortem examination. Remission lasted longer in stage III than in stage IV and the previously untreated patients responded better than the treated ones. Definite correlation could not be revealed between histologic type and duration of remission.

UR - http://www.scopus.com/inward/record.url?scp=0016699322&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0016699322&partnerID=8YFLogxK

M3 - Article

C2 - 1098868

AN - SCOPUS:0016699322

VL - 21

SP - 248

EP - 254

JO - Chemotherapy

JF - Chemotherapy

SN - 0009-3157

IS - 3-4

ER -